<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03515993</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-1514-QLG-GCG</org_study_id>
    <nct_id>NCT03515993</nct_id>
  </id_info>
  <brief_title>Follow-up in Gynecological Cancer Survivors</brief_title>
  <official_title>Follow-up in Gynecological Cancer Survivors: An EORTC QLG-GCG Survivorship Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A cross-sectional prospective study of follow-up in gynecologic cancer patients after primary
      treatment
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to identify physical and psychosocial problems and needs after
      treatment for gynecological cancer.

      1100 patients stratified by cancer sites and treatment - a minimum of 120 patients within
      each stratum - will be recruited.

      Institutional data on follow-up policy, demographic and clinical data (related to treatment
      history and tumor characteristics) will be collected. Patients will complete a set of 76
      Quality of Life questions, at one single time point.

      Descriptive analyses will be conducted to characterize the collected data. Multivariate model
      building will be used to identify patterns of physical, psychological and social problems
      based on factors specific to the patient and to the disease. Logistic multinomial or
      continuous regression analysis will be used to investigate which socio-demographic, clinical
      variables, or institutional are associated significantly with compromised quality of life and
      sexual health outcomes. Exploratory factor analysis will be used to explore the factor
      structure of the various PROMs to identify issue clustering.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 21, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>15 months after first patient inclusion</time_frame>
    <description>It will be evaluated using self-administered EORTC QLQ-C30 questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>15 months after first patient inclusion</time_frame>
    <description>It will be evaluated using self-administered questions on anxiety (from the EORTC quality of life item library)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>15 months after first patient inclusion</time_frame>
    <description>It will be evaluated using self-administered EORTC OUT-PATSAT-C7 questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>15 months after first patient inclusion</time_frame>
    <description>It will be evaluated using self-administered EORTC Sexual Health Questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>15 months after first patient inclusion</time_frame>
    <description>It will be evaluated using self-administered Distress Thermometer</description>
  </primary_outcome>
  <enrollment type="Anticipated">1100</enrollment>
  <condition>Gynecologic Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Gynecologic cancer patients after primary treatment attending participating hospitals for
        routine follow-up.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological proven gynecological cancer (cervical, endometrial, ovarian (including
             fallopian tube and peritoneal primary), vulva).

          -  FIGO stage I-IV before completion of primary therapy.

          -  Disease-free without any evidence of relapse: no symptoms or signs potentially
             indicating recurrent disease (assessed according to standard clinical parameters using
             physical and gynecological examination, blood tests, CA 125 (ovarian cancer), or
             radiological imaging techniques).

          -  At least 6 months but no more than 5 years since completion of primary treatment.

          -  Performance status 0, 1 or 2 (WHO scale).

          -  Age â‰¥ 18 years.

          -  Ability to understand and fill out questionnaires.

          -  Written informed consent according to ICH/GCP, and national/local regulations.

        Exclusion Criteria:

          -  Other cancer diagnosis in the past 5 years.

          -  Patients participating in interventional clinical studies with Quality of Life as
             primary endpoint.

          -  Any psychological (including pre-existing psychiatric disorders), familial,
             sociological or geographical condition potentially hampering compliance with the study
             protocol and follow-up schedule.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>EORTC HQ</last_name>
    <phone>+32 2 774 1611</phone>
    <email>1514@eortc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Greimel</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori IRCCS &quot;Fondazione G. Pascale&quot;</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefano Greggi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>King Hussein Cancer Center</name>
      <address>
        <city>Amman</city>
        <zip>11941</zip>
        <country>Jordan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abdulmajeed Dayyat, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Radboudumc - Radboud University Medical Center Nijmegen</name>
      <address>
        <city>Nijmegen</city>
        <zip>NL 6525</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petronella Beatrix Ottevanger</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UMC-Academisch Ziekenhuis Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>NL 3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eleonora van Dorst</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University Of Gdansk</name>
      <address>
        <city>Gdansk</city>
        <zip>PL 80 211</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dagmara Klasa-Mazurkiewicz</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Casado</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Navarra</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Elena Villafranca Iturre</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>East Kent Hospitals University NHS Foundation Trust - Queen Elizabeth The Queen Mother Hospita</name>
      <address>
        <city>Margate</city>
        <state>Kent</state>
        <zip>CT9 4AN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Nordin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northampton General Hospital NHS Trust</name>
      <address>
        <city>Cliftonville</city>
        <state>Northampton</state>
        <zip>NN1 5BD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roshan Agarwal</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NHS Greater Glasgow and Clyde - Beatson West of Scotland Cancer Centre - Gartnavel General Hospital</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Azmat Hassan Sadozye</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Italy</country>
    <country>Jordan</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>March 30, 2018</study_first_submitted>
  <study_first_submitted_qc>April 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2018</study_first_posted>
  <last_update_submitted>March 11, 2020</last_update_submitted>
  <last_update_submitted_qc>March 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>long-term survival</keyword>
  <keyword>gynecologic cancer</keyword>
  <keyword>quality of life</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

